Skip to main content
Premium Trial:

Request an Annual Quote

Iris Completes Purchase of AlliedPath for Up to $6M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Iris International said today it has completed its acquisition of AlliedPath for up to $6 million.

The deal was originally announced last week and includes $4.7 million in cash to AlliedPath and up to $1.3 million in an earn-out, subject to certain sales and earnings targets being met over the next three years.

AlliedPath is based in San Diego and was founded in 2008. It specializes in oncology and molecular diagnostics and received its CLIA license in 2009. Its laboratory is 10,000 square feet.

In a statement, Cesar Garcia, chairman and CEO of Iris, said that the purchase is a "significant step forward" for Iris and provides it with a CLIA-certified molecular pathology lab "offering differentiated high-value molecular diagnostic services in the rapidly growing field of personalized medicine."

The deal also offers a direct commercial channel for acceleration of Iris' NADiA nucleic acid detection immunoassay platform, Garcia added.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.